At which point and for which reasons are oral MTX formulations switched to injectable ones in RA patients? combined results from 3 independent observational and clinical trials - Archive ouverte HAL Accéder directement au contenu
Poster De Conférence Année : 2018

At which point and for which reasons are oral MTX formulations switched to injectable ones in RA patients? combined results from 3 independent observational and clinical trials

Fichier non déposé

Dates et versions

hal-01828999 , version 1 (03-07-2018)

Identifiants

  • HAL Id : hal-01828999 , version 1

Citer

Rene Marc Flipo, Alain Saraux, Christophe Hudry, Cecile Gaujoux-Viala, Eric Senbel, et al.. At which point and for which reasons are oral MTX formulations switched to injectable ones in RA patients? combined results from 3 independent observational and clinical trials. EULAR 2018, Jun 2018, Amsterdam, Netherlands. Annals of the Rheumatic Diseases, 77, pp.985. ⟨hal-01828999⟩
27 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More